There are nearly 20 neglected tropical diseases that afflict countless people in poor countries across the globe, but developing useful treatments can be an uphill battle when the pharmaceutical industry often emphasizes medicines that are designed to generate large profits. So Mark Sullivan, a former clinical researcher at Gilead Sciences and GlaxoSmithKline, formed a not-for-profit company called Medicines Development for Global Health in his native Australia. With financial backing from a socially minded investment fund and the cooperation of the World Health Organization, he is about to launch a treatment for river blindness that was recently approved by the FDA. The attempt marks a new model for tackling such diseases and, possibly, for other ailments, too. We spoke with him about the effort. This is an edited version of our conversation.

Pharmalot: So you worked in big pharma for many years. What did you do and what prompted you to go down this path?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy